Business
Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of tar
About this update from Clarity Pharmaceuticals Ltd.
[{"type":"text","content":"SYDNEY, April 14, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the signing of a Commercial Manufacturing Agreement for 64Cu-SAR-bisPSMA with Nucleus RadioPharma, an innovative contract development and manufacturing organisation (CDMO) in the radiopharmaceutical industry, dedicated to the development and manufacturing of targeted radiotherapies.","length":580,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Clarity Pharmaceuticals)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Clarity Pharmaceuticals)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":98,"url":"https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vmE_hah3MeiZkntL_jHvXA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3Mw--/https://media.zenfs.com/en/prnewswire.com/2ced23e8ddb3b1ec6ef537b99f6e12a7","width":400,"height":98}},"href":"https://mma.prnewswire.com/media/1700068/Clarity_Large_Logo_high_res_ID_42691c6bc5c0_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The Agreement relates to Nucleus RadioPharma's state-of-the-art facility in Rochester, Minnesota, which is capable of manufacturing around 50,000 patient doses per year, and future production in Spring House, Pennsylvania. The Spring House facility is a 47,000 square foot site that is planned to open in 2028, enabling broad coverage across the northeast of the US with up to 600,000 doses of 64Cu-SAR-bisPSMA per year. Together, these two facilities in Minnesota and Pennsylvania will provide access to key commercial markets with manufacturing and distribution to all 50 states in the US and select international sites, including Europe.","length":644,"tagName":"p"},{"type":"text","content":"The Commercial Manufacturing Agreement further builds on Clarity's existing partnership with Nucleus RadioPharma with a Master Services Agreement and 67Cu-SAR-bisPSMA Clinical Supply Agreement in place from November 20241, covering the existing site in Rochester with additional facilities in Pennsylvania2 and future strategic sites to expand patient ac...